Anzeige
❌
Mehr »
Mittwoch, 07.10.2026 - Börsentäglich über 12.000 News

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
ACCESS Newswire
302 Leser
Artikel bewerten:
(1)

CeCors, Inc.: PsyKey Inc Completes Definitive Agreement with MycoVita to establish a Strategic Partnership focused on Research, Development and Commercialization of Mycology based Products

CARSON CITY, NV / ACCESSWIRE / May 11, 2021 / CECORS, INC. (OTC PINK:CEOS) ("CeCors" or the "Company"), through its wholly-owned subsidiary PsyKey Inc. is pleased to announce it has entered into a definitive agreement to form an exclusive strategic partnership with MycoVita Canada Inc., that is expected to accelerate the growth and market share for both companies, in the fast-growing mycology-based markets. The Partnership will be executed via a wholly-owned subsidiary of PsyKey Inc. with the purpose of the Partnership being the Research, development, and commercialization of Mycology based formulations, products, and therapeutics, as well as the development of innovative sustainable food production strategies.

MycoVita is a Biotech company focused on the development of functional foods and products, that support optimal health and wellbeing through science-backed formulations and research. MycoVita holds numerous formulations that are composed of natural occurring compounds sourced only from the highest quality raw ingredients, under the supervision and guidance of its world-class team.

The MycoVita team includes Dr. Omon Isikhuemhen who is an internationally recognized researcher and professor in the field of mushroom science and fungal biotechnology. Dr. Isikhuemhen's credentials include a Bachelor of Science with honors, a Master's of Science in Botany, as well as a Doctor of Philosophy in Microbiology. Dr. Isikhuemhen is a trailblazer in research and development that has resulted in numerous scientific publications and technological advancements.

This strategic partnership will provide PsyKey Inc. exclusive access to formulations, science-backed research, supply chain security, and new potential distribution channels.

"Partnering with MycoVita will not only provide PsyKey the opportunity to offer consumers unmatched quality and efficacy in its product offerings, but it will also open doors in the mushroom industry and mycology world by working alongside Dr. Isikhuemhen. This will allow us to further gain and develop opportunity to provide long-term growth and new revenue streams for the company," said Amar Bhatal, president of CeCors Inc.

For further information:

Publicly traded company (OTC PINK:CEOS)
Website: www.psykeyworld.com
E-mail: info@psykeyworld.com
Follow us on Twitter: https://twitter.com/PsyKeyworld

Forward-Looking Statements:

Safe Harbour Statement - In addition to historical information, this press release may contain statements that constitute forward-looking statements within the meaning of the Securities Act of 1933 and the Securities Exchange Act of 1934, as amended by the Private Securities Litigation Reform Act of 1995. Forward-looking statements contained in this press release include the intent, belief, or expectations of the Company and members of its management team with respect to the Company's future business operations and the assumptions upon which such statements are based. Prospective investors are cautioned that any such forward-looking statements are not guarantees of future performance, and involve risks and uncertainties and that actual results may differ materially from those contemplated by such forward-looking statements. Factors that could cause these differences include, but are not limited to, failure to complete anticipated sales under negotiations, lack of revenue growth, client discontinuances, failure to realize improvements in performance, efficiency, and profitability, and adverse developments with respect to litigation or increased litigation costs, the operation or performance of the Company's business units or the market price of its common stock. Additional factors that could cause actual results to differ materially from those contemplated within this press release can also be found on the Company's website. The Company disclaims any responsibility to update any forward- looking statements.

SOURCE: CeCors, Inc.



View source version on accesswire.com:
https://www.accesswire.com/646220/PsyKey-Inc-Completes-Definitive-Agreement-with-MycoVita-to-establish-a-Strategic-Partnership-focused-on-Research-Development-and-Commercialization-of-Mycology-based-Products

© 2021 ACCESS Newswire
KI-Euphorie kippt - Bei diesen 5 Aktien droht der Crash!
Drei Jahre lang kannten KI-Aktien fast nur eine Richtung: nach oben. Billionenschwere Investitionspläne von Alphabet, Amazon, Meta und Microsoft haben Halbleiter- und Infrastrukturwerte auf immer neue Höhen getrieben. Doch jetzt bekommt die Erfolgsstory gefährliche Risse.

Steigende Anleiherenditen verteuern die Finanzierung, während die gewaltigen KI-Ausgaben zunehmend nicht mehr aus den laufenden Cashflows bezahlt werden können. Gleichzeitig zeigen günstigere chinesische Modelle, dass leistungsfähige KI womöglich mit deutlich weniger Rechenleistung auskommt. Damit wächst die Gefahr, dass heute für Milliarden errichtete Kapazitäten morgen nicht die erhofften Renditen liefern.

Für Anleger könnte das zum Problem werden. Denn treffen steigende Finanzierungskosten auf Überkapazitäten und enttäuschende Cashflows, geraten gerade hoch bewertete KI-Profiteure schnell unter Druck. Aus den größten Gewinnern der vergangenen Jahre könnten so die größten Verlierer der nächsten Korrektur werden.

In unserem aktuellen Spezialreport zeigen wir 5 Aktien, bei denen das Chance-Risiko-Verhältnis jetzt besonders gefährlich erscheint – und bei denen Anleger genauer hinschauen sollten.

Jetzt den kostenlosen Report sichern – bevor die KI-Euphorie ihren nächsten Realitätstest erlebt!
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.